Tradestie Institutional Equity Comparison Engine

CORT vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CORT Overall Edge

CORT Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Corcept Therapeutics Inc. (CORT) driven by superior Valuation, Growth & Margin, Options & Structure while SYRE counters with relative strength in Momentum & Technical. Fundamentally, CORT trades at 14.6x Forward P/E with 11.5% operating margin (+64.0% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CORT sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CORT
CORT 14.6x vs SYRE N/M Fwd P/E
Growth & Margin Winner CORT
Op Margin 11.5% vs 0.0% ยท YoY +64.0% vs +0.0%
Momentum & Technical Winner SYRE
1Y -8.7% vs +341.7% ยท 52W Pos 42% vs 88%
Options & Structure Winner CORT
CONSOLIDATION (10th %ile IV) vs UNCLASSIFIED (10th %ile IV)
CORT NASDAQ
Corcept Therapeutics Inc.
Pharmaceutical Preparations
$69.17
-5.17% 1D
Market Cap $8.1B
1M Return -37.21%
1Y Return -8.69%
Forward P/E 14.6x
Unified AI Score
50.7 / 100 HOLD
Tech 45.0 Fund 55.0 Flow 67.0 Mom 55.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CORT -8.69% SYRE +341.74% Spread: +350.43 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CORT TTM Op. Margin: 11.5% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CORT vs SYRE. Trailing 12-month operating profitability (CORT 11.5% vs SYRE 0.0%) and valuation multiples (CORT 14.6x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CORT (7) vs SYRE (3)
Institutional Metric CORT SYRE Criterion Row Winner
Market Capitalization Scale $8.1B $9.8B Larger Scale SYRE
Trailing P/E Ratio Valuation 55.4x N/M Lower Multiple CORT
Forward P/E Ratio Valuation 14.6x N/M Lower Multiple CORT
Revenue Growth (YoY) Growth +64.0% +0.0% Higher Growth CORT
Operating Margin (TTM) Profitability 11.5% 0.0% Higher Margin CORT
Net Profit Margin Profitability 16.8% 0.0% Higher Margin CORT
Return on Equity (ROE) Capital Efficiency 22.1% -35.0% Higher ROE CORT
52-Week Range Position Momentum 42% ($29โ€“$126) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.63ฮฒ ยท 85% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 50.7 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite CORT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CORT vs SYRE Buy Guide
CORT CONSOLIDATION
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live CORT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CORT nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.